**27 February 2023**

**MPOX - CLAIMING GUIDE FOR PRIMARY CARE**

**PURPOSE**

This document provides guidance on nationally set fees that can be claimed by primary care providers (general practice and pharmacy), urgent care and afterhours providers to 30 June 2023.

**FEES SCHEDULE**

Conditions for claiming include:

* No fee to patient (including general practice/Hauora providers/other co-payments and prescription co-payments).
* No claim for clawback for general practice/Hauora providers/others.
* No simultaneous claiming against any other funding stream.
* All dollar values **exclude GST**.
* Contract funding cancellation will be given in writing with 30 days' notice if prior to 30 June 2023

|  |  |  |
| --- | --- | --- |
| **General Practice/Hauora Providers/Others** | **Description** | **Claim** |
|
| **Assessment, Testing, Treatment** | In-person assessment, includes testing and prescription (30 minutes) | $180.00 |
| Follow up appointments – if positive for MPox (15 minutes) | $90.00 |
| **Urgent Care / Afterhours Care** | In-person assessment, includes testing and prescription | $270.00 |
| **Urgent Care / Afterhours Care** | Follow up appointment – within 2 weeks of initial assessment related to MPox (15 minutes) | $135.00 |

**CLAIMING PROCESS**

* Claims should be invoiced as per standard invoicing practice
* Follow-up consultations for management of new and worsening conditions related to confirmed positive MPox test
* Maximum of one consultation per day
* Patient initiated consultation for follow-up

Note: Funding is only available for those who meet eligibility criteria and / or are requested by local Medical Officer of Health

|  |  |  |
| --- | --- | --- |
| **Pharmacy Service** | **Description** | **Claim** |
|
| **Dispensing Service** | Tecovirimat dispensing in a community pharmacy, including unapproved medicine (section 29) reporting requirements | $15.00 |
| **Delivery Cost** | Reimbursement for delivery of a single or multiple medicines as needed. | $7.00 |
| **Prescription Co-Payment** | Reimbursement of prescription co-payment per, non-tecovirimat, MPox related treatment  | $4.35 |

**APPENDIX 1 Pharmacy Service Guidance**

1. **Service components**

1.1 The Provider must obtain tecovirimat from the pharmaceutical wholesaler approved by Pharmac (currently Healthcare Logistics (HCL).

1.2 If a pharmacy does not have an account with HCL please contact them on 09 969 0736 to arrange an account.

1.3 The cost of the tecovirimat is free to the provider including the cost of the medicine and courier to the pharmacy.

1.4 Tecovirimat can be ordered from HCL from 31 October 2022.

1.5 Tecovirimat should only be ordered upon receipt of a prescription, and not ordered in anticipation of receiving a prescription.

1.6 Non tecovirmat MPox treatments

1. **Service linkages**

2.1 The Provider must establish and maintain linkages with the local general practices.

1. **Performance Measures**
	1. The effectiveness of this service will be monitored through data capture in your PhMS and captured in the NZePS.
	2. Tecovirimat is an unapproved medicine. The Provider must work with the supplying pharmaceutical wholesaler to provide the standard unapproved medicine reporting to Medsafe. Further details can be found on the [Medsafe website](https://www.medsafe.govt.nz/regulatory/unapproved.asp).

*Fees, payments, and claiming rules*

1. **Payment for tecovirimat**

4.1 The publicly funded oral antiviral medicines are supplied to the participating pharmacy at zero cost.

4.2 Providers will receive payment for the Service through a variation to their COVID Care in the Community Pharmacy agreement with their Te Whatu Ora district

1. dispensing tecovirimat in a community pharmacy fee is $15 (GST exclusive)
2. delivery fee of tecovirimat $7.00 (GST exclusive).
3. no simultaneous claiming against any other funding stream
4. funding is only available for those who meet eligibility criteria and / or are requested by the local Medical Officer of Health.

4.3 Claims should be invoiced as indicated in your COVID Care in the Community Pharmacy agreement.

1. **Payment for non-tecovirimat monkeypox treatments**
	1. MPox treatments that are not tecovirimat need to be endorsed ‘MPox treatment no co-payment' or similar
2. **No payment to be sought from Eligible Service Users**
	1. The Provider must not in any circumstances demand or accept any Product Premium, Pharmacy Charge, Co-payment, or any other fee from any Eligible Service User to whom the Provider provides oral MPox antiviral medicines under this service specification.